Medically reviewed by Femi Aremu, PharmD Complement 3 glomerulopathy (C3G) is a rare type of kidney disease. There are two types: C3 glomerulonephritis (C3GN) and dense deposit disease (DDD).C3GN is ...

Apellis Pharmaceuticals (APLS) stock gains as Bank of America upgrades the firm, citing a strong commercial rollout of its ...

Sweden’s Sobi has announced that the European Commission (EC) has approved Aspaveli (pegcetacoplan) for adults and ...

Sobi® (STO: SOBI), today announced that the European Commission (EC) has approved Aspaveli® (pegcetacoplan) for the treatment of adult and adolescent patients aged 12 to 17 years with C3 ...

Approximately 8,000 people in Europe are living with C3G or primary IC-MPGN Aspaveli (pegcetacoplan) is the first treatment of primary IC-MPGN and the first treatment for C3G and primary IC-MPGN ...

Medically reviewed by Erika Prouty, PharmD Key Takeaways There are two types of complement 3 glomerulopathy: dense deposit ...

Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% ...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you design and create an advertising campaign, in print and digital, on this ...

The glomerulonephritis market is witnessing steady growth driven by the increasing prevalence of chronic kidney diseases and improved diagnostic capabilities. Additionally, ongoing clinical trial ...

Bonn, October 15, 2025 – Will it be possible to treat severe kidney inflammation with fewer drugs in the future? A new study by the University Hospital Bonn (UKB), the University of Bonn, and the ...

What Is Empaveli, and Why Does It Matter? First approved in 2021 for a rare blood disorder, Empaveli (pegcetacoplan) is now approved as the first targeted medicine for adults and children aged 12 ...